CD8A and ocular melanoma: Similarly, in phase 3, GEMCOVAC-OM showed an increase in IFNγ+CD8+ T cells from baseline to day 29 and a significantly higher expression of TNF+CD4+, IL-2+CD4+ and IL-2+CD8+ T cells at day 29 compared with ChAdOx1 nCoV-19.